TPPP2 as a Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: TPPP2

NCBI ID: G122664

TPPP2

TPPP2 as a Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue that affects millions of people worldwide. The persistent nature of pain can lead to significant morbidity and disability in individuals, and the economic burden of chronic pain is substantial. The pain management market is estimated to be worth over $300 billion globally, with muscle relaxants and opioids being the most commonly prescribed medications. However, these medications have several drawbacks, including potential addiction, abuse, and negative side effects. The search for new and more effective pain treatments has led to the exploration of alternative biomarkers and drug targets. TPPP2, a protein p25-beta, has emerged as a promising candidate for the treatment of chronic pain.

TPPP2: Structure and Function

TPPP2 is a 21-kDa protein that is expressed in various tissues, including muscle, tendon, and bone. It is a key regulator of the cytoskeleton, and its dysfunction has been implicated in the development and maintenance of chronic pain. TPPP2 functions as a scaffold protein, helping to maintain the integrity of the cytoskeleton and cell organization during development, maintenance, and repair.

The p25-beta subunit of TPPP2 is a key regulator of the cytoskeleton, as it plays a critical role in the regulation of cell shape and movement. The p25-beta subunit is composed of two transmembrane domains (TMDs) and a cytoplasmic tail. The TMDs contain a unique ATP-binding site that is involved in the regulation of actinin cytoskeleton.

TPPP2 has been shown to play a role in the regulation of pain perception and the modulation of pain modalities. Several studies have demonstrated that TPPP2 is involved in the regulation of pain processing and neuroinflammation. For instance, TPPP2 has been shown to modulate the activity of pain-related GABA receptors, which are involved in the regulation of pain perception. Additionally, TPPP2 has been shown to play a role in the regulation of pro-inflammatory cytokines, such as TNF-alpha and IL-1尾, which are involved in the modulation of pain perception and the regulation of inflammation.

Drug Targeting Strategies for TPPP2

TPPP2 has been identified as a potential drug target for the treatment of chronic pain due to its involvement in the regulation of pain perception and inflammation. Several drug targeting strategies have been proposed to target TPPP2 and its function.

1. Small Molecule Inhibitors:

Several small molecules have been shown to be potent inhibitors of TPPP2, including inhibitors of the ATP-binding site and the cytoplasmic tail. One such inhibitor, N1-215, is an inhibitor of the ATP-binding site that has been shown to significantly reduce the activity of TPPP2 in cell culture and in animal models of pain. Similarly, inhibitors of the cytoplasmic tail, such as N1-10 and N1-19, have also shown promise in the inhibition of TPPP2.

1. Peptide-Based Therapeutics:

Peptides have been shown to be effective in the inhibition of TPPP2, particularly when used in combination with small molecules. One such peptide, Y1-234, is a fragment of the TPPP2 cytoplasmic tail that has been shown to inhibit the activity of TPPP2 in cell culture and in animal models of pain. When used in combination with N1-19, a small molecule inhibitor of the ATP-binding site, Y1-234 has been shown to be effective in the inhibition of TPPP2-mediated pain.

1. DNA-Based Therapeutics:

Recent studies have shown the potential of DNA-based therapeutics in the inhibition of TPPP2. DNA-based therapeutics can be used to deliver small molecules or antibodies to specific target

Protein Name: Tubulin Polymerization Promoting Protein Family Member 2

Functions: Probable regulator of microtubule dynamics required for sperm motility (Probable). In contrast to other members of the family, has no microtubule bundling activity (PubMed:17105200)

The "TPPP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPPP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets